Abstract:Abstract The epidermal growth factor receptor (EGFR) is a prime target for cancer therapy across many solid tumor types, including CRC, NSCLC, breast, esophageal cancer, and SCCHN. Binding of EGFR by its ligand EGF induces cell proliferation, a process which is uncontrolled or constitutively active in many cancers. The development of anti-EGFR therapies such as monoclonal antibodies and tyrosine kinase inhibitors enabled clinicians to treat specific patient populations. Nevertheless, prognoses for patients remain unfavorable due to occurrence of intrinsic or acquired resistance via mutations of EGFR and/or downstream signaling factors such as KRAS and BRAF which are drivers of tumorigenesis. Inhibitors that target specific KRAS mutations, such as the G12C mutation (i.e. 14% of the most frequently observed in NSCLC and up to 5% in CRC), have shown early promising efficacy. While such drugs hold promise for specific mutations, there continues to be a need for new treatments with more differentiated and novel modes of action that utilize the power of the innate immune system, such as antibody dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP). Affimed has engineered the tetravalent bispecific EGFR- and CD16A-binding antibody AFM24 to engage and redirect innate immune cells such as NK cells and macrophages to EGFR+ tumor cells. In contrast to currently available EGFR-targeted therapies (e.g. cetuximab), this innate cell engager has been designed to exhibit a significantly reduced inhibition of EGFR signaling aiming for an improved safety profile, i.e. avoiding skin and gastro-intestinal toxicities. In vitro, AFM24 demonstrated high affinity binding to immune cells regardless of CD16A variants and potent killing of multiple EGFR+ tumor cell lines, carrying relevant KRAS or BRAF mutations via a different mode of action, namely ADCC and ADCP, rather than EGFR signaling inhibition. It was shown that AFM24's activity is independent of both, the EGFR cell surface expression level and the cellular origin of the respective cell lines. Cynomolgus toxicity studies revealed a very good safety profile, and no toxicity was observed after repeated administration (q7x28d, in total 5 infusions) of AFM24 up to 75 mg/kg. In contrast, EGFR-targeting mAbs (e.g. cetuximab) exhibited severe toxicities particularly in skin in toxicology studies when investigated with a similar dosing schedule. Due to its potent activation of innate immunity and its beneficial safety/tolerability profile, AFM24 has the potential to become a novel treatment option for patients suffering from EGFR-expressing cancers and to overcome limitations of available EGFR-targeted therapies such as resistance and/or associated toxicities. AFM24 has cleared the IND and clinical investigations are planned in patients with cancers known to express EGFR. Citation Format: Uwe Reusch, Michael Damrat, Susanne Wingert, Stefan H.J. Knackmuss, Thomas Mueller, Ivica Fucek, Ute Schniegler-Mattox, Kristina Ellwanger, Torsten Haneke, Andras Strassz, Wolfgang Fischer, Erich Rajkovic, Michael Tesar. AFM24, a bispecific EGFR/CD16A innate cell engager with the potential to overcome resistance to current targeted treatments for EGFR-positive malignancies [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 5659.

Abstract 6353: AM105: A novel bispecific antibody with Anti 4-1BB affibodies and EGFR antibody

Abstract 5675: Discovery and development of an asymmetric IgG-like bispecific antibody targeting EGFR and c-MET, engineered through H-H and H-L chain charge-based heterodimerization

Abstract 6366: The triple-specific antibody KA-3009 against EGFR, B7H3, and 4-1BB specifically enhances T cell activity within the tumor

Abstract 5083: Discovery of an asymmetric IgG-like bispecific ADC targeting EGFR/HER3

Abstract 6354: The HER2/4-1BB bispecific antibody, YH32367 (ABL105) demonstrates optimal efficacy and safety for HER2-expressing tumors and exhibits synergistic efficacy when combined with anti-PD-L1

Abstract 5555: A bispecific antibody targeting CLDN18.2 and 4-1BB induces potent anti-tumor efficacy with an extraordinary safety profile

Abstract 2619: A novel EGFR × HER3-targeting bispecific antibody drug-conjugate, BCG019, demonstrates robust anti-tumor efficacy in preclinical evaluation

Abstract 2710: Developing a novel doppel-targeting antibody-drug conjugate (ADC) for solid cancer

Abstract 5316: SM2256: A bispecific conditional CD40 and 4-1BB dual agonist for enhanced solid tumor immune response

Abstract 1341: SM2235: A bispecific EGFR x CD16A innate immune cell engager for enhanced treatment of EGFR-expressing solid tumors, regardless of RAS mutation status

Abstract 2380: The bispecific antibody KA-3004, targeting PD-L1 and 4-1BB, is designed to enhance anti-tumor activity

Abstract 5299: A novel anti-4-1BB antibody with no liver toxicity and its application in a bi-specific antibody

Abstract 522: Optimization of Novel Anti-4-1bb Antibodies on Biocytogen's in Vivo Drug Screening Platform

Abstract 2618: BCG017, a bispecific ADC targeting PTK7 and EGFR exhibits anti-tumor efficacy in PDX models

Abstract 5659: AFM24, a bispecific EGFR/CD16A innate cell engager with the potential to overcome resistance to current targeted treatments for EGFR-positive malignancies

Abstract 5303: A novel TIGIT and 4-1BB bispecific antibody, ABL112, exhibits potent in vitro and in vivo antitumor activity through dual immune modulation

Abstract 2650: Pre-clinical Efficacy and Toxicity Profile of LM-24C5: A Novel CEACAM5 X 4-1BB Bispecific Antibody in Cancer Immunotherapy

Abstract 2715: Preclinical characterization of SM2248: A dual-action bispecific antibody enhancing immunotherapy for solid tumors

Abstract 3189: A novel monoclonal antibody targeting TM4SF4 enhances antitumor activity through regulation of cellular levels of immune checkpoint ligands and antibody dependent cellular cytotoxicity

Abstract 2620: BCG016, a first-in-class bispecific antibody-drug conjugate targeting 5T4 and MUC1, demonstrates potent preclinical anti-tumor activity

Abstract 5304: ABL407, a LILRB4x4-1BB bispecific antibody with a wild type Fc, exhibits potent antitumor activity by modulating immune system in multiple ways involving T cells, myeloids, and regulatory T cells